Dr. Baiocchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
5th Floor
Columbus, OH 43210Phone+1 614-293-3196Fax+1 614-293-4812
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
- Ohio State University HospitalResidency, Internal Medicine, 1999 - 2001
- Ohio State University College of MedicineClass of 1999
- SUNY BUffaloMD, medicine, 1995 - 1997
- State University of New York CollegePh.D, Physiology, 1994
- State University of New York CollegeM.S., Natural Science, 1993
- State University of New York CollegeB.S., Biology, 1989
Certifications & Licensure
- OH State Medical License 2000 - 2025
Awards, Honors, & Recognition
- Early Career Innovator of the Year Nomination The Ohio State University, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Innovation Award-Semi Finalist Inventor of the Year Nomination Tech Columbus, 2011
- Join now to see all
Clinical Trials
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
- Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 29 citationsEndogenous CD8+ T Cell Expansion During Regression of Monoclonal EBV-Associated Posttransplant Lymphoproliferative DisorderVijay P. Khatri, Robert A. Baiocchi, Ruoqi Peng, Adam R. Oberkircher, Jean Dolce
Journal of Immunology. 1999-07-01 - 1 citationsPhase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-...Missak Haigentz Jr, Jeannette Y Lee, Elizabeth Y Chiao, David M Aboulafia, Lee Ratner
Clinical Cancer Research. 2023-12-15 - 53 citationsLymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10Robert A. Baiocchi, Mary Ellen Ross, Jian Tan, Chuan-Chu Chou, L Sullivan
Blood. 1995-02-15
Journal Articles
- ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative exerts potent cytotoxicity in mantle cell lymphoma in-vitro and in-vivoMani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N, Exp Hematol, 1/1/2015
- AIDS Malignancy Consortium AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphomaNoy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L, Blood, 1/1/2015
- The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and ref...Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Br J Haematol, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell LymphomaRobert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Targeting Hypersumoylation in Mantle Cell LymphomaRobert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Post graduate career options for the physician scientistChicago, IL - 1/26/2015
- Targeting Histone Methyltransferases and Demethylases trackBoston, MA - 1/24/2015
- Join now to see all
Press Mentions
- OSU Doctor Looks into Viruses That May Lead to CancerMay 11th, 2019
- Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
- Possible New Target for Future Brain Cancer DrugsFebruary 27th, 2014
- Join now to see all
Grant Support
- Development Of Novel Compounds To Inhibit PRMT5 Enzyme In High Grade AstrocytomasNational Institute Of Neurological Disorders And Stroke2010–2011
- Development Of Vaccine Strategies To Prevent EBV+ Lymphoma In Patients With HIVNational Cancer Institute2009–2010
- Ptld: Cytokine Production And Gene PolymorphismsNational Cancer Institute2005
- Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: